Atlas
Back to RCM
Legal / Service Provider·RCM

Angela Humphreys

Chair of the Healthcare Practice Group and Co-Chair of the Healthcare Private Equity Team at Bass, Berry & Sims PLC

Nashville, Tennessee, USA

AH
LinkedIn
Why they matter

She has led $60B+ in healthcare M&A, including WellCare-Centene, and is a go-to regulatory counsel for PE sponsors buying provider and payer-adjacent platforms.

Background

Angela Humphreys chairs the Healthcare Practice Group and co-chairs the Healthcare Private Equity Team at Bass, Berry & Sims in Nashville. Over a 23+ year career spent exclusively in healthcare and life sciences M&A, she has led deals with a combined value exceeding $60 billion, spanning physician practice management platforms, dental service organizations, ambulatory surgery centers, and health plans. She began her career in public accounting (CPA, now inactive) before earning her J.D. at the University of Tennessee College of Law.

Notable deals

  • 2020
    Led the Bass, Berry & Sims team representing WellCare Health Plans in its $17.3 billion merger with Centene Corporation
  • 2025
    Core member of the ~20-attorney team serving as healthcare regulatory counsel to Sycamore Partners in its up-to-$23.7 billion acquisition of Walgreens Boots Alliance
  • 2025
    Named to Mergers & Acquisitions' Most Influential Women in Mid-Market M&A
  • 2019
    Appointed co-chair of Bass, Berry & Sims' Healthcare Private Equity Team, alongside her role chairing the firm's nationally ranked Healthcare Practice

Call-prep brief

Background

  • 23+ years exclusively in healthcare and life sciences M&A at Bass, Berry & Sims (Nashville); chairs the Healthcare Practice Group and co-chairs the Healthcare Private Equity Team (since 2019).
  • Started in public accounting (inactive CPA) — comfortable in the financial mechanics of deals, not just the legal ones.
  • Recognitions: Law360 Health Law MVP (2018), Mergers & Acquisitions' Most Influential Women in Mid-Market M&A (2025).

Current focus

  • PE investment in specialty providers, physician practice management, ASCs, DSOs, and payer-adjacent services.
  • Publicly active in 2025-26 on state legislatures targeting healthcare PE (transaction-review statutes) and the 2026 healthcare M&A outlook.
  • Recent marquee work: healthcare regulatory counsel to Sycamore Partners on the $23.7B Walgreens Boots Alliance take-private (closed August 2025).

What they care about

  • Regulatory-driven deal structuring: getting sponsors through diligence and state approval regimes without repricing or breakage.
  • The firm's national healthcare franchise — she is a rainmaker with deal flow visibility across dozens of sponsors.

Potential sensitivities

  • Will not discuss active client matters; expect a conflicts check before any engagement.
  • She is a counsel relationship and referral channel, not an operator — frame the call around market perspective and future mandates.

Questions to ask

  1. Which state transaction-review laws are most affecting how sponsors structure RCM and provider-services deals for 2026?
  2. Where is she seeing sponsor appetite shift within revenue cycle and physician-adjacent services?
  3. What regulatory diligence issues most often reprice or kill RCM platform acquisitions?

Outreach draft

Subject
Healthcare PE regulatory landscape — quick call
Dear Ms. Humphreys, I'm on the investment team at a private equity firm evaluating platform opportunities in healthcare revenue cycle and provider-adjacent services. Your work leading WellCare's merger with Centene and, more recently, the healthcare regulatory workstream on Sycamore's Walgreens acquisition makes your perspective on the current environment especially valuable — particularly as state legislatures sharpen their focus on healthcare PE. Would you be open to a 30-minute call in the coming weeks to compare notes on the regulatory landscape and where you see transaction activity heading in 2026? Happy to work around your schedule. Best regards, [Name]

Linked companies

Sources